Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and tr… Read more
Roche Holding AG (RHHBF) - Net Assets
Latest net assets as of December 2025: $37.88 Billion USD
Based on the latest financial reports, Roche Holding AG (RHHBF) has net assets worth $37.88 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($100.70 Billion) and total liabilities ($62.82 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $37.88 Billion |
| % of Total Assets | 37.62% |
| Annual Growth Rate | 5.2% |
| 5-Year Change | 33.64% |
| 10-Year Change | 43.47% |
| Growth Volatility | 11.73 |
Roche Holding AG - Net Assets Trend (2014–2025)
This chart illustrates how Roche Holding AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Roche Holding AG (2014–2025)
The table below shows the annual net assets of Roche Holding AG from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $37.88 Billion | +4.75% |
| 2024-12-31 | $36.16 Billion | +8.71% |
| 2023-12-31 | $33.26 Billion | +3.90% |
| 2022-12-31 | $32.02 Billion | +12.95% |
| 2021-12-31 | $28.34 Billion | -28.73% |
| 2020-12-31 | $39.77 Billion | +10.89% |
| 2019-12-31 | $35.87 Billion | +18.12% |
| 2018-12-31 | $30.37 Billion | +4.69% |
| 2017-12-31 | $29.01 Billion | +9.87% |
| 2016-12-31 | $26.40 Billion | +13.55% |
| 2015-12-31 | $23.25 Billion | +7.24% |
| 2014-12-31 | $21.68 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Roche Holding AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 85.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $48.84 Billion | 144.48% |
| Total Equity | $33.80 Billion | 100.00% |
Roche Holding AG Competitors by Market Cap
The table below lists competitors of Roche Holding AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Raytheon Technologies Corp
NYSE:RTX
|
$253.87 Billion |
|
UnitedHealth Group Incorporated
NYSE:UNH
|
$256.27 Billion |
|
Nestle SA
PINK:NSRGF
|
$258.19 Billion |
|
Agricultural Bank of China PK
PINK:ACGBY
|
$259.69 Billion |
|
The Goldman Sachs Group, Inc.
LSE:0R3G
|
$241.92 Billion |
|
SAP SE
PINK:SAPGF
|
$238.59 Billion |
|
Goldman Sachs Group Inc
NYSE:GS
|
$236.20 Billion |
|
Wells Fargo & Company
NYSE:WFC
|
$235.14 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Roche Holding AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 31,767,000,000 to 33,802,000,000, a change of 2,035,000,000 (6.4%).
- Net income of 12,880,000,000 contributed positively to equity growth.
- Dividend payments of 7,731,000,000 reduced retained earnings.
- Other factors decreased equity by 2,127,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $12.88 Billion | +38.1% |
| Dividends Paid | $7.73 Billion | -22.87% |
| Other Changes | $-2.13 Billion | -6.29% |
| Total Change | $- | 6.41% |
Book Value vs Market Value Analysis
This analysis compares Roche Holding AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.93x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $0.00 | $336.92 | x |
| 2016-12-31 | $0.00 | $336.92 | x |
| 2017-12-31 | $30.97 | $336.92 | x |
| 2018-12-31 | $32.35 | $336.92 | x |
| 2019-12-31 | $38.27 | $336.92 | x |
| 2020-12-31 | $42.60 | $336.92 | x |
| 2021-12-31 | $28.67 | $336.92 | x |
| 2022-12-31 | $35.03 | $336.92 | x |
| 2023-12-31 | $36.77 | $336.92 | x |
| 2024-12-31 | $39.87 | $336.92 | x |
| 2025-12-31 | $42.49 | $336.92 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Roche Holding AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 38.10%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.33%
- • Asset Turnover: 0.63x
- • Equity Multiplier: 2.98x
- Recent ROE (38.10%) is below the historical average (40.48%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 47.65% | 18.71% | 0.66x | 3.86x | $7.42 Billion |
| 2015 | 42.25% | 17.58% | 0.67x | 3.61x | $6.75 Billion |
| 2016 | 40.05% | 18.93% | 0.66x | 3.21x | $7.18 Billion |
| 2017 | 32.65% | 16.20% | 0.70x | 2.90x | $5.99 Billion |
| 2018 | 38.01% | 18.47% | 0.72x | 2.84x | $7.74 Billion |
| 2019 | 41.22% | 21.96% | 0.74x | 2.54x | $10.22 Billion |
| 2020 | 39.34% | 24.51% | 0.68x | 2.37x | $10.66 Billion |
| 2021 | 56.88% | 22.18% | 0.68x | 3.77x | $11.48 Billion |
| 2022 | 44.37% | 19.63% | 0.72x | 3.15x | $9.62 Billion |
| 2023 | 39.22% | 19.02% | 0.67x | 3.09x | $8.57 Billion |
| 2024 | 26.06% | 13.27% | 0.61x | 3.20x | $5.10 Billion |
| 2025 | 38.10% | 20.33% | 0.63x | 2.98x | $9.50 Billion |
Industry Comparison
This section compares Roche Holding AG's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $355,057,678,100
- Average return on equity (ROE) among peers: -0.02%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Roche Holding AG (RHHBF) | $37.88 Billion | 47.65% | 1.66x | $243.19 Billion |
| AbbVie Inc (ABBV) | $15.70 Billion | 26.61% | 0.35x | $387.90 Billion |
| Astellas Pharma Inc (ALPMF) | $1.46 Trillion | 8.50% | 0.60x | $16.93 Billion |
| Amgen Inc (AMGN) | $80.60 Million | 0.62% | 0.16x | $194.15 Billion |
| Amarin Corporation PLC (AMRN) | $24.15 Million | -158.05% | 0.75x | $303.32 Million |
| AstraZeneca PLC (AZN) | $14.91 Billion | 37.51% | 2.22x | $295.24 Billion |
| Bayer AG (BAYZF) | $20.80 Billion | 15.33% | 1.47x | $21.61 Billion |
| Biogen Inc (BIIB) | $6.43 Billion | 19.21% | 0.41x | $27.11 Billion |
| Bristol-Myers Squibb Company (BMY) | $4.75 Billion | 22.46% | 0.58x | $121.36 Billion |
| Chugai Pharmaceutical Co. Ltd (CHGCF) | $2.03 Trillion | 21.42% | 0.22x | $28.30 Billion |
| Cosmo Pharmaceuticals N.V (CMOPF) | $58.37 Million | 6.18% | 0.57x | $529.97 Million |